Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 6/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 11/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4634778 | 0.81 | PTGER3 (0.37) | PTGER3PTGER1PTGER4PTGER2HDAC4 | |
| SCHEMBL4634780 | 0.81 | PTGER3 (0.37) | PTGER3PTGER1PTGER4PTGER2HDAC4 | |
| SCHEMBL17094885 | 0.61 | RAB9A (0.44) | MAPTPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6421622 | 0.60 | PTGER3 (0.57) | PTGER3PTGER1PTGER4PTGER2 | |
| SCHEMBL3973206 | 0.59 | PTGER3 (0.49) | PTGER3PTGER1PTGER4PTGER2 | |
| SCHEMBL5697665 | 0.59 | PTPN7 (0.61) | PPARGMAPTPSEN1PSEN2APH1B | |
| Acetic Acid SCHEMBL4133191 | 0.58 | HDAC4 (0.35) | HDAC4HDAC8PPARG | |
| SCHEMBL12687868 | 0.58 | HDAC6 (0.58) | HDAC8PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3973201 | 0.58 | PTGER3 (0.47) | PTGER3PTGER1PTGER4PTGER2 | |
| SCHEMBL9919131 | 0.56 | EGFR (0.43) | PTGER3PTGER1PTGER4PTGER2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | claimed |
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | PTPRF, PTPA, PTPRJ | PTGER3 3188/4885PTGER1 1399/4885PTGER4 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.